These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 25076257)

  • 21. Pazopanib for the treatment of renal cancer.
    Al-Marrawi MY; Rini B
    Expert Opin Pharmacother; 2011 May; 12(7):1171-89. PubMed ID: 21470066
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pazopanib for the treatment of renal cell carcinoma.
    Welsh SJ; Fife K
    Future Oncol; 2015; 11(8):1169-79. PubMed ID: 25832874
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pazopanib versus sunitinib in metastatic renal-cell carcinoma.
    Motzer RJ; Hutson TE; Cella D; Reeves J; Hawkins R; Guo J; Nathan P; Staehler M; de Souza P; Merchan JR; Boleti E; Fife K; Jin J; Jones R; Uemura H; De Giorgi U; Harmenberg U; Wang J; Sternberg CN; Deen K; McCann L; Hackshaw MD; Crescenzo R; Pandite LN; Choueiri TK
    N Engl J Med; 2013 Aug; 369(8):722-31. PubMed ID: 23964934
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Case records of the Massachusetts General Hospital. Case 17-2008. A 63-year-old man with metastatic renal-cell carcinoma.
    Michaelson MD; Iliopoulos O; McDermott DF; McGovern FJ; Harisinghani MG; Oliva E
    N Engl J Med; 2008 May; 358(22):2389-96. PubMed ID: 18509125
    [No Abstract]   [Full Text] [Related]  

  • 25. Words of wisdom: Re: Pazopanib versus sunitinib in metastatic renal-cell carcinoma.
    Sun M; Trinh QD; Perrotte P; Karakiewicz PI
    Eur Urol; 2014 May; 65(5):1014-5. PubMed ID: 24646500
    [No Abstract]   [Full Text] [Related]  

  • 26. Words of wisdom: Re: Pazopanib versus sunitinib in metastatic renal-cell carcinoma.
    Ouzaid I; Rini B
    Eur Urol; 2014 Mar; 65(3):667-8. PubMed ID: 24484761
    [No Abstract]   [Full Text] [Related]  

  • 27. Efficacy and safety of pazopanib in patients with metastatic renal cell carcinoma.
    Hutson TE; Davis ID; Machiels JP; De Souza PL; Rottey S; Hong BF; Epstein RJ; Baker KL; McCann L; Crofts T; Pandite L; Figlin RA
    J Clin Oncol; 2010 Jan; 28(3):475-80. PubMed ID: 20008644
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pazopanib as third line therapy for metastatic renal cell carcinoma: clinical efficacy and temporal analysis of cytokine profile.
    Pal SK; Hossain DM; Zhang Q; Frankel PH; Jones JO; Carmichael C; Ruel C; Lau C; Kortylewski M
    J Urol; 2015 Apr; 193(4):1114-21. PubMed ID: 25286010
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effectiveness of pazopanib and SBRT in metastatic renal cell carcinoma.
    Cihan YB
    World J Urol; 2018 Nov; 36(11):1797-1798. PubMed ID: 29740689
    [No Abstract]   [Full Text] [Related]  

  • 30. Good tolerability, long-term survival and easy management of side effects in a patient with metastatic renal cell carcinoma treated with pazopanib.
    Frascaroli M; Di Cesare P
    Tumori; 2014; 100(6):e301-4. PubMed ID: 25688516
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Overall survival in renal-cell carcinoma with pazopanib versus sunitinib.
    Motzer RJ; Hutson TE; McCann L; Deen K; Choueiri TK
    N Engl J Med; 2014 May; 370(18):1769-70. PubMed ID: 24785224
    [No Abstract]   [Full Text] [Related]  

  • 32. Pazopanib versus sunitinib in renal cancer.
    Wittes J
    N Engl J Med; 2013 Nov; 369(20):1969. PubMed ID: 24224637
    [No Abstract]   [Full Text] [Related]  

  • 33. Pazopanib versus sunitinib in renal cancer.
    Casper J; Schumann-Binarsch S; Köhne CH
    N Engl J Med; 2013 Nov; 369(20):1969. PubMed ID: 24224638
    [No Abstract]   [Full Text] [Related]  

  • 34. Pazopanib versus sunitinib in renal cancer.
    Ramaekers R; Tharnish M; Copur MS
    N Engl J Med; 2013 Nov; 369(20):1968-9. PubMed ID: 24224636
    [No Abstract]   [Full Text] [Related]  

  • 35. Pazopanib versus sunitinib in renal cancer.
    Motzer RJ; McCann L; Deen K
    N Engl J Med; 2013 Nov; 369(20):1970. PubMed ID: 24224635
    [No Abstract]   [Full Text] [Related]  

  • 36. A Phase II Study of Pazopanib in Patients with Localized Renal Cell Carcinoma to Optimize Preservation of Renal Parenchyma.
    Rini BI; Plimack ER; Takagi T; Elson P; Wood LS; Dreicer R; Gilligan T; Garcia J; Zhang Z; Kaouk J; Krishnamurthi V; Stephenson AJ; Fergany A; Klein EA; Uzzo RG; Chen DY; Campbell SC
    J Urol; 2015 Aug; 194(2):297-303. PubMed ID: 25813447
    [TBL] [Abstract][Full Text] [Related]  

  • 37. First-Line and Sequential Use of Pazopanib Followed by Mammalian Target of Rapamycin Inhibitor Therapy Among Patients With Advanced Renal Cell Carcinoma in a US Community Oncology Setting.
    Vogelzang NJ; Hackshaw MD; Hutson TE; Bhowmik D; Yap M; Rembert D; Jonasch E
    Clin Genitourin Cancer; 2015 Jun; 13(3):210-7. PubMed ID: 25498215
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Prognostic or predictive plasma cytokines and angiogenic factors for patients treated with pazopanib for metastatic renal-cell cancer: a retrospective analysis of phase 2 and phase 3 trials.
    Tran HT; Liu Y; Zurita AJ; Lin Y; Baker-Neblett KL; Martin AM; Figlin RA; Hutson TE; Sternberg CN; Amado RG; Pandite LN; Heymach JV
    Lancet Oncol; 2012 Aug; 13(8):827-37. PubMed ID: 22759480
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Initial experience with first-line pazopanib in the treatment of metastatic renal cell carcinoma: A single institution data.
    Joshi A; Agarwala V; Ramaswamy A; Noronha V; Patil VM; Menon S; Popat P; Sable N; Prabhash K
    Indian J Cancer; 2016; 53(4):575-578. PubMed ID: 28485355
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Rationale and protocol of SOAP: a phase II study to evaluate the efficacy of sorafenib as second-line treatment after pazopanib in patients with advanced renal cell carcinoma.
    Iacovelli R; Verzoni E; Grassi P; Farcomeni A; de Braud F; Procopio G
    Tumori; 2014; 100(6):e282-5. PubMed ID: 25688511
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.